Biofourmis

AI Healthcare Tools AI Research & Education Tools

↳AI Remote Patient Monitoring ↳AI Medical Research & Clinical Decision Support

Enterprise

AI remote patient monitoring with 120+ biomarkers — Hospital@Home and predictive care delivery

Not yet rated

Released 2015

Visit Website

Gallery

4 items

VIDEO

About Biofourmis

Biofourmis is a global AI-powered digital health company that combines continuous wearable biosensor monitoring, advanced machine learning, and virtual care delivery to bring hospital-level clinical care into patients' homes. Founded in 2015 in Boston by scientists and cardiologists, Biofourmis has raised $461.85M in total funding and achieved unicorn status at a $1.3B valuation. In October 2024, Biofourmis merged with CopilotIQ to form an end-to-end AI-driven in-home care platform spanning acute, post-acute, and chronic care.

At the core of Biofourmis is its Biovitals platform \u2014 an FDA-cleared AI analytics engine that continuously ingests data from wearable sensors and patient health histories to analyze 120+ biomarkers in real time, building personalized physiological models that detect early signs of health deterioration days before a critical event occurs. Its Hospital@Home solution enables health systems to provide inpatient-level care for qualifying patients at home, reducing costly readmissions while improving patient experience. BiovitalsHF received FDA Breakthrough Device Designation for heart failure management, helping clinicians optimize medication dosage and monitor for adverse drug reactions remotely. The platform integrates natively with Epic EHR and supports chronic condition management, oncology monitoring, and post-acute care transitions.

Biofourmis is the right choice for health systems, integrated delivery networks, and payers seeking enterprise-grade AI-powered remote patient monitoring with predictive analytics and proven clinical validation \u2014 particularly organizations scaling hospital-at-home programs or value-based care models.

Key Features

Biovitals RPM platform — analyzes 120+ biomarkers in real time from FDA-approved wearable biosensors
Hospital@Home — delivers hospital-level care at home, reducing readmission rates and inpatient bed usage
BiovitalsHF — FDA Breakthrough Device for heart failure: optimizes medication, detects adverse reactions remotely
AI predictive analytics — machine learning models detect patient deterioration days before a critical event
Epic EHR integration — seamless data flow into existing hospital information systems
Care@Home platform — manages patients across the full continuum from acute to chronic care
Oncology remote monitoring — tracks cancer patients at home via Gaido Health integration
Personalized physiological models — individual patient baselines for highly accurate deterioration detection
Digital therapeutics pipeline — software-based therapies in development for heart failure
Value-based care alignment — platform links patient outcomes to payment models for health systems and payers

Pros

FDA 510(k) cleared + FDA Breakthrough Device Designation for BiovitalsHF — highest regulatory validation in RPM
$461.85M raised, $1.3B unicorn valuation — General Atlantic, CVS Health, SoftBank Vision Fund 2 backing
120+ biomarker real-time analysis — most comprehensive predictive RPM analytics platform available
Proven clinical outcomes — reduces hospital readmissions and enables earlier intervention days before events
Epic EHR integration — fits natively into existing health system infrastructure without workflow disruption
Merged with CopilotIQ (Oct 2024) — expanded to end-to-end AI in-home care across all care stages
Hospital@Home validated program — one of few platforms with proven acute-care-at-home deployment at scale

Cons

Enterprise-only pricing — no self-service or SMB option
Implementation complexity — requires EHR integration and clinical workflow setup
No public pricing — evaluation requires direct sales engagement
Life sciences division divested to ActiGraph (Jan 2025)
Primarily US-focused deployment despite global presence
Not available to individual clinicians or small practices

Pricing

Biofourmis is an enterprise-only platform with no public pricing. All contracts are custom, negotiated directly with health systems, IDNs, hospitals, and payers.

Pricing is based on patient volume, care program type (Hospital@Home, chronic disease management, post-acute care), integration requirements, and contract term. The platform is typically deployed under value-based care arrangements where costs are linked to patient outcomes and readmission reduction.

Contact Biofourmis through biofourmis.com to request a demo and enterprise pricing discussion.

Claim Verified Creator Badge

Are you the founder of Biofourmis? Display this listing's verified badge on your website to show your customers that your product has been vetted and listed on AI Central Resources.

HTML Embed Code

<a href="https://www.aicentralresources.com/tool/biofourmis" target="_blank" rel="noopener">
  <img src="https://www.aicentralresources.com/badges/featured-badge-dark.svg" alt="Featured on AICentralResources" width="200" height="54" style="border: none;" />
</a>

* Place this HTML snippet in your website's footer, landing page, or press section. This creates a search-friendly backlink directly to your verification page.

Connect with Biofourmis

X (Twitter)LinkedIn

Frequently Asked Questions

Biofourmis is an AI-powered remote patient monitoring platform that continuously tracks patients via FDA-approved wearable biosensors and analyzes 120+ biomarkers in real time. Its machine learning engine builds personalized physiological models for each patient, detecting early signs of deterioration days before a critical event and alerting care teams to intervene proactively.

Hospital@Home is Biofourmis's solution that enables health systems to deliver inpatient-level care in patients' homes for qualifying conditions. It combines continuous remote monitoring, virtual nursing, and on-demand in-home clinical visits to manage patients who would otherwise require a hospital bed, reducing costs and freeing inpatient capacity.

BiovitalsHF is Biofourmis's AI platform for remote heart failure management. It received FDA Breakthrough Device Designation in 2021, making it one of the first digital therapeutics for heart failure to receive this designation. It helps clinicians optimize medication dosage, monitor for adverse drug reactions, and detect worsening heart failure remotely.

In October 2024, Biofourmis merged with CopilotIQ, a General Atlantic-backed AI chronic care platform, forming an end-to-end AI in-home care platform. In January 2025, the life sciences/clinical trial division (Biofourmis Connect) was separately acquired by ActiGraph.

Biofourmis serves large health systems, integrated delivery networks, hospitals, and payers including AdventHealth in Central Florida. The platform suits organizations deploying Hospital@Home, chronic disease management at scale, post-surgical monitoring, and value-based care models.